Miss Llinos Honeybun
Research student
- HoneybunLS@cardiff.ac.uk
- Sir Martin Evans Building, Museum Avenue, Cardiff, CF10 3AX
- Welsh speaking
Overview
I'm a PhD student working in Dr Emyr Lloyd-Evans' lab investigating new treatments for a rare childhood neurodegenerative disorder called CLN3 disease (also referred to as Batten disease). This disorder affects children from the age of 4+ and symptoms include loss of vision, seizures and later, motor and cognitive decline. There are currently no treatments for these children and I hope to uncover some effective therapies during my PhD.
Publication
2023
- Lloyd-Evans, E., Best, H. L., Alshehri, A. S., Honeybun, L. and Waller-Evans, H. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 84., (10.1016/j.ymgme.2022.107212)
- Waller-Evans, H., Zhu, J., Honeybun, L., Gardiner, S., Hanley, M., Best, H. and Lloyd-Evans, E. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 133-134., (10.1016/j.ymgme.2022.107353)
- Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 167-167., (10.1016/j.ymgme.2022.107150)
- Best, H., Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 47-47., (10.1016/j.ymgme.2022.107030)
Conferences
- Lloyd-Evans, E., Best, H. L., Alshehri, A. S., Honeybun, L. and Waller-Evans, H. 2023. Glycosphingolipid reduction with miglustat as a therapeutic strategy for CLN3 and other neuronal ceroid lipofuscinoses.. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 84., (10.1016/j.ymgme.2022.107212)
- Waller-Evans, H., Zhu, J., Honeybun, L., Gardiner, S., Hanley, M., Best, H. and Lloyd-Evans, E. 2023. Measuring ion flux via lysosomal channels: Primary and secondary assays for drug discovery across the lysosomal disorders. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 133-134., (10.1016/j.ymgme.2022.107353)
- Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. Unbiased phenotypic drug screen for CLN3 disease. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 167-167., (10.1016/j.ymgme.2022.107150)
- Best, H., Honeybun, L., Waller-Evans, H. and Lloyd-Evans, E. 2023. The Batten disease associated protein CLN3 is required for the efflux of lysosomal K. Presented at: 19th Annual WORLDSymposium™ 2023, Orlando, Florida, 21-26 February 2023, Vol. 138. Vol. 2. Elsevier pp. 47-47., (10.1016/j.ymgme.2022.107030)
Research